Skip to main content

Advertisement

Celecoxib: a selective cyclooxygenase-2 inhibitor

Article metrics

  • 1047 Accesses

Selective cyclooxygenase-2 (COX-2) inhibitors were developed to fill an important medical need. The rationale for the development of selective COX-2 inhibitors will be discussed using celecoxib as an example. A brief description of the pharmacology and selective binding to the COX-2 enzyme will be presented. Both preclinical and clinical data will be shown to demonstrate important clinical aspects of celecoxib. The efficacy data will include studies of osteoarthritis, rheumatoid arthritis, and acute pain conditions. Both gastroenterology and cardiovascular safety of celecoxib will be discussed. Finally, potential new therapeutic areas for celecoxib will be presented.

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Gandelman, M. Celecoxib: a selective cyclooxygenase-2 inhibitor. Arthritis Res Ther 5, 172 (2003) doi:10.1186/ar973

Download citation

Keywords

  • Public Health
  • Rheumatoid Arthritis
  • Arthritis
  • Clinical Data
  • Osteoarthritis